upgrad buy covid cocktail move clinic june
increas rate hold buy price target due
possibl prophylaxi treatment schedul move clinic
june base regn comment fda prioriti review accept
ebola antibodi cocktail becom like regn
antibodi cocktail might use prophylaxi treatment high-risk individu
opinion
april regn co-found georg yancopoulo mention
antibodi cocktail treat bridg vaccin potenti
becom even power vaccin although think antibodi
cocktail may limit healthcar profession individu high
exposur infect
mr yancopoulo also mention capac produc hundr
thousand possibl mani million dose per month cocktail
prove success number potenti capac impli
antibodi cocktail might use prophylaxi rather treatment
april fda accept regn bla prioriti review ebola
antibodi cocktail think prioriti review consider regn-
show fda willingness/inclin consid emerg approv
potenti antibodi cocktail also mention
antibodi cocktail move preclinical- clinical-scal cell product
initi clinic studi june
dont model kevzara sale even kevzara potenti becom clinic
success kevzara market product establish price antibodi
cocktail price turn limit exist standard believ
singl administr antibodi cocktail price per
singl administr importantli use prophylaxi measur
million patient possibl vaccin
eventu develop
new price target buy rate reflect revenu
increas due antibodi cocktail sale prophylaxi purpos howev
assign probabl success antibodi cocktail treatment thu
view regn target price opportunist
mm except per share data fy risk-adjust regeneron sale eylea-u libtayo sanofi collabor bayer collabor pipelin product risk-adjusted- covid cocktail risk-adjusted- total revenu collabor contract gross oper expensesresearch develop adjust research develop share-bas compens total share-bas gener administr adjust sell gener administr share-bas compens total share-bas share-bas compens exclud non- op ex sg total oper expens cog oper incom interest total non-oper incom pre-tax incom incom tax benefit tax incom basic share outstand dilut share outstand dilut share outstand eop excl ep ep
benchmark co llc analyst whose name appear front page research report certifi recommend
opinion express herein accur reflect research analyst person view subject secur issu
discuss herein furthermor part research analyst compens directli indirectli relat specif
recommend view express research analyst research report
march
buy stock expect outperform analyst defin
sector/industri follow month
hold stock expect perform in-lin analyst
defin sector/industri follow
sell stock expect under-perform analyst defin
sector/industri follow month
expect outperform follow
market weight analyst defin sector/industri
expect perform in-lin
follow month
expect under-perform follow
month
past month benchmark affili manag
co-manag public offer secur subject compani
benchmark and/or affili expect receiv intend seek
compens invest bank servic subject
compani next three month
research analyst member research analyst household
associ research analyst individu directli
involv prepar report long posit
share deriv subject compani
research analyst member research analyst household
associ research analyst individu directli
involv prepar report short posit
share deriv subject compani
member research analyst household serv offic
director advisori board member subject compani
month end immedi preced date public
report prior month end public within day
follow month end benchmark affili aggreg
benefici own class equiti secur
partner director offic employe agent benchmark
member his/her household offic director advisor board
member subject compani and/or one subsidiari
benchmark make market secur subject compani
past month benchmark partner affili offic
director analyst involv prepar report
provid non-invest bank securities-rel servic
subject compani remuner
past month benchmark partner affili offic
director analyst involv prepar report
provid non-secur relat servic subject compani
remuner
benchmark compani disclosur april
